TP53突变识别出无法从强化化学免疫治疗中获益的年轻套细胞淋巴瘤患者
研究分析183例来自北欧MCL2和MCL3试验的年轻套细胞淋巴瘤患者诊断期骨髓标本,探索复发性遗传异常的预后价值。多变量分析显示仅TP53突变对总生存期有独立预后影响(HR 6.2,P<.0001),TP53突变患者中位OS仅1.8年,而未突变者中位OS为12.7年。作者建议按TP53状态对MCL患者进行分层,TP53突变患者应考虑参加探索新药的实验性一线试验。
要点
- TP53突变见于11%的年轻MCL患者,与不良预后显著相关。
- TP53突变患者中位OS为1.8年,未突变者为12.7年(P<.0001)。
- 作者建议TP53突变患者考虑参加探索新药的实验性一线试验。
核心结论
- TP53突变识别出一种表型独特且高度侵袭性的套细胞淋巴瘤,对包含阿糖胞苷、利妥昔单抗和自体干细胞移植的方案反应差或无反应。
- 作者建议套细胞淋巴瘤患者应按TP53状态进行分层,TP53突变患者应考虑参加探索新药的实验性一线试验。
研究设计与样本
- 研究纳入来自北欧MCL2和MCL3试验的183例年轻套细胞淋巴瘤患者,分析其诊断期骨髓标本中复发性遗传异常的预后价值。
- MCL2和MCL3试验代表当前标准治疗 regimen。
主要发现
- 单变量模型中,TP53突变(11%)、NOTCH1突变(4%)、TP53缺失(16%)和CDKN2A缺失(20%)与较差结局显著相关(连同MIPI、MIPI-c、母细胞样形态和Ki67>30%)。
- 多变量分析中,仅TP53突变对总生存期保留预后影响(HR 6.2,P<.0001);TP53突变(HR 6.9,P<.0001)和MIPI-c高危(HR 2.6,P=.003)对至复发时间有独立预后影响。
- TP53突变患者中位OS为1.8年,50%在1.0年时复发;TP53未突变患者中位OS为12.7年(P<.0001)。
- TP53突变与Ki67>30%、母细胞样形态、MIPI高危以及对诱导化疗和高剂量化疗反应差显著相关。
临床怎么用
- 作者建议套细胞淋巴瘤患者应按TP53状态进行分层。
- 作者建议TP53突变患者应考虑参加探索新药的实验性一线试验。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite recent advances in lymphoma treatment, mantle cell lymphoma (MCL) remains incurable, and we are still unable to identify patients who will not benefit from the current standard of care. Here, we explore the prognostic value of recurrent genetic aberrations in diagnostic bone marrow (BM) specimens from 183 younger patients with MCL from the Nordic MCL2 and MCL3 trials, which represent current standard-of-care regimens. In the univariate model, mutations of TP53 (11%) and NOTCH1 (4%), and deletions of TP53 (16%) and CDKN2A (20%), were significantly associated with inferior outcomes (together with MIPI, MIPI-c, blastoid morphology, and Ki67 > 30%); however, in multivariate analyses, only TP53 mutations (HR, 6.2; P < .0001) retained prognostic impact for overall survival (OS), whereas TP53 mutations (HR, 6.9; P < .0001) and MIPI-c high-risk (HR, 2.6; P = .003) had independent prognostic impact on time to relapse. TP53-mutated cases had a dismal outcome, with a median OS of 1.8 years, and 50% relapsed at 1.0 years, compared to a median OS of 12.7 years for TP53-unmutated cases (P < .0001). TP53 mutations were significantly associated with Ki67 > 30%, blastoid morphology, MIPI high-risk, and inferior responses to both induction- and high-dose chemotherapy. In conclusion, we show that TP53 mutations identify a phenotypically distinct and highly aggressive form of MCL with poor or no response to regimens including cytarabine, rituximab, and autologous stem-cell transplant (ASCT). We suggest patients with MCL should be stratified according to TP53 status, and that patients with TP53 mutations should be considered for experimental frontline trials exploring novel agents.
引用
- Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017. PMID: 28819011. doi:10.1182/blood-2017-04-779736
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。